AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dexketoprofen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibuprofen derivatives | 833 | 22161-81-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a water-soluble tromethamine salt of the racemic ketoprofen, rac(+-)-ketoprofen
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 75 | mg | O |
| 75 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,EIF2AK3,GRK2,PDK1,PDK2,PDK4 | 6 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,PDK4,PIK3CD | 5 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 1.574 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis | 119.50 | 32.88 | 38 | 2169 | 25305 | 90600935 |
| Pancreatic failure | 81.50 | 32.88 | 16 | 2191 | 1476 | 90624764 |
| Acute kidney injury | 68.77 | 32.88 | 59 | 2148 | 320328 | 90305912 |
| Drug interaction | 67.79 | 32.88 | 55 | 2152 | 276398 | 90349842 |
| Angioedema | 63.05 | 32.88 | 31 | 2176 | 64845 | 90561395 |
| Coagulopathy | 62.84 | 32.88 | 23 | 2184 | 23266 | 90602974 |
| Hepatic cytolysis | 59.96 | 32.88 | 24 | 2183 | 30892 | 90595348 |
| Hyperbilirubinaemia | 53.89 | 32.88 | 18 | 2189 | 13918 | 90612322 |
| Hepatic perfusion disorder | 51.36 | 32.88 | 7 | 2200 | 62 | 90626178 |
| Lichen planus | 45.05 | 32.88 | 11 | 2196 | 2780 | 90623460 |
| Neutrophil toxic granulation present | 44.69 | 32.88 | 7 | 2200 | 172 | 90626068 |
| Toxicity to various agents | 38.69 | 32.88 | 41 | 2166 | 287805 | 90338435 |
| Hyperamylasaemia | 36.89 | 32.88 | 7 | 2200 | 539 | 90625701 |
| Anaphylactic reaction | 36.35 | 32.88 | 24 | 2183 | 87500 | 90538740 |
| Jaundice | 35.98 | 32.88 | 17 | 2190 | 32500 | 90593740 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperaesthesia | 123.04 | 30.45 | 32 | 1801 | 5920 | 42613582 |
| Quality of life decreased | 101.96 | 30.45 | 27 | 1806 | 5349 | 42614153 |
| Polyneuropathy in malignant disease | 87.57 | 30.45 | 15 | 1818 | 361 | 42619141 |
| Allodynia | 71.58 | 30.45 | 15 | 1818 | 1079 | 42618423 |
| Sleep deficit | 50.52 | 30.45 | 11 | 1822 | 948 | 42618554 |
| Metastases to lung | 47.39 | 30.45 | 18 | 1815 | 11406 | 42608096 |
| Acute kidney injury | 44.86 | 30.45 | 66 | 1767 | 367271 | 42252231 |
| Application site pain | 40.82 | 30.45 | 11 | 1822 | 2318 | 42617184 |
| Dermatitis allergic | 37.48 | 30.45 | 14 | 1819 | 8469 | 42611033 |
| Application site erythema | 35.20 | 30.45 | 10 | 1823 | 2556 | 42616946 |
| Drug dependence | 34.02 | 30.45 | 19 | 1814 | 29075 | 42590427 |
| Metastases to bone | 33.08 | 30.45 | 15 | 1818 | 14794 | 42604708 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 109.78 | 26.12 | 125 | 3922 | 635305 | 109949947 |
| Hyperaesthesia | 99.35 | 26.12 | 32 | 4015 | 14695 | 110570557 |
| Tubulointerstitial nephritis | 91.41 | 26.12 | 43 | 4004 | 54241 | 110531011 |
| Polyneuropathy in malignant disease | 85.65 | 26.12 | 15 | 4032 | 486 | 110584766 |
| Drug interaction | 85.53 | 26.12 | 98 | 3949 | 500085 | 110085167 |
| Quality of life decreased | 84.30 | 26.12 | 28 | 4019 | 14141 | 110571111 |
| Hyperbilirubinaemia | 76.45 | 26.12 | 32 | 4015 | 30639 | 110554613 |
| Pancreatic failure | 67.71 | 26.12 | 16 | 4031 | 2338 | 110582914 |
| Allodynia | 64.34 | 26.12 | 15 | 4032 | 2068 | 110583184 |
| Hepatic cytolysis | 64.22 | 26.12 | 34 | 4013 | 55019 | 110530233 |
| Angioedema | 62.46 | 26.12 | 41 | 4006 | 98459 | 110486793 |
| Coagulopathy | 55.59 | 26.12 | 28 | 4019 | 40883 | 110544369 |
| Hypocoagulable state | 50.97 | 26.12 | 13 | 4034 | 2602 | 110582650 |
| Hepatic perfusion disorder | 48.40 | 26.12 | 7 | 4040 | 63 | 110585189 |
| Sleep deficit | 45.43 | 26.12 | 11 | 4036 | 1781 | 110583471 |
| Drug reaction with eosinophilia and systemic symptoms | 42.13 | 26.12 | 30 | 4017 | 82065 | 110503187 |
| Hyperkalaemia | 40.38 | 26.12 | 36 | 4011 | 135760 | 110449492 |
| Neutrophil toxic granulation present | 39.55 | 26.12 | 7 | 4040 | 241 | 110585011 |
| Hepatitis cholestatic | 39.35 | 26.12 | 17 | 4030 | 17549 | 110567703 |
| Metastases to lung | 37.96 | 26.12 | 18 | 4029 | 23045 | 110562207 |
| Application site pain | 33.23 | 26.12 | 11 | 4036 | 5488 | 110579764 |
| Dermatitis allergic | 32.86 | 26.12 | 16 | 4031 | 21708 | 110563544 |
| Toxicity to various agents | 32.69 | 26.12 | 61 | 3986 | 480494 | 110104758 |
| Upper gastrointestinal haemorrhage | 32.09 | 26.12 | 21 | 4026 | 50075 | 110535177 |
| Hepatocellular injury | 31.88 | 26.12 | 21 | 4026 | 50621 | 110534631 |
| Bradyphrenia | 31.79 | 26.12 | 13 | 4034 | 11715 | 110573537 |
| Lichen planus | 29.64 | 26.12 | 9 | 4038 | 3401 | 110581851 |
| Intentional overdose | 29.60 | 26.12 | 30 | 4017 | 132471 | 110452781 |
| Application site erythema | 29.08 | 26.12 | 10 | 4037 | 5600 | 110579652 |
| Hyperamylasaemia | 28.43 | 26.12 | 7 | 4040 | 1214 | 110584038 |
| Drug dependence | 27.32 | 26.12 | 19 | 4028 | 50001 | 110535251 |
| Fracture displacement | 27.13 | 26.12 | 7 | 4040 | 1465 | 110583787 |
| Urea renal clearance decreased | 27.10 | 26.12 | 4 | 4043 | 42 | 110585210 |
| Metabolic acidosis | 26.81 | 26.12 | 25 | 4022 | 99719 | 110485533 |
| Glaucoma | 26.50 | 26.12 | 14 | 4033 | 22503 | 110562749 |
| Benign prostatic hyperplasia | 26.29 | 26.12 | 13 | 4034 | 18221 | 110567031 |
| Chronic kidney disease | 26.25 | 26.12 | 22 | 4025 | 76269 | 110508983 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AE17 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Propionic acid derivatives |
| ATC | M02AA27 | MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use |
| ATC | N02AJ14 | NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:50629 | cyclooxygenase 2 inhibitor |
| CHEBI has role | CHEBI:50630 | cyclooxygenase 1 inhibitor |
| CHEBI has role | CHEBI:73336 | vulnerary |
Related Drugs by ATC class:
M01AE Propionic acid derivatives 21 drugs
M02AA Antiinflammatory preparations, non-steroids for topical use 28 drugs
N02AJ Opioids in combination with non-opioid analgesics 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.28 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 7.57 | CHEMBL | KEGG DRUG | |||
| Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 8.72 | CHEMBL | KEGG DRUG |
External reference:
| ID | Source |
|---|---|
| 6KD9E78X68 | UNII |
| D07269 | KEGG_DRUG |
| 233386 | RXNORM |
| C0772505 | UMLSCUI |
| CHEBI:76128 | CHEBI |
| 9KL | PDB_CHEM_ID |
| CHEMBL75435 | ChEMBL_ID |
| 667550 | PUBCHEM_CID |
| DB09214 | DRUGBANK_ID |
| 7120 | INN_ID |
| C118296 | MESH_SUPPLEMENTAL_RECORD_UI |
| 007781 | NDDF |
| 007782 | NDDF |
| 329961001 | SNOMEDCT_US |
| 396018005 | SNOMEDCT_US |
| 427618005 | SNOMEDCT_US |
| 6KD9E78X68 | INXIGHT DRUGS |
Pharmaceutical products:
None